Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment The VAST-D Randomized Clinical Trial

Mohamed Somaia; Johnson Gary R.; Chen Peijun; Hicks Paul B.; Davis Lori L.; Yoon Jean; Gleason Theresa C.; Vertrees Julia E.; Weingart Kimberly; Tal Ilanit; Scrymgeour Alexandra; Lawrence David D.; Planeta Beata; Thase Michael E.; Huang Grant D.; Zisook Sidney

首页> 外文期刊>JAMA: the Journal of the American Medical Association >Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment The VAST-D Randomized Clinical Trial

【24h】

Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment The VAST-D Randomized Clinical Trial

机译：抗抑郁切换对抗抑郁治疗患者抗抑郁治疗患者缓解抗抑郁治疗的影响

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

IMPORTANCE Less than one-third of patients with major depressive disorder (MDD) achieve remission with their first antidepressant.

机译：少于三分之一的患者的主要抑郁症（MDD）达到了第一个抗抑郁药的缓解。

著录项

来源
《JAMA: the Journal of the American Medical Association》 |2017年第2期|共14页
作者
Mohamed Somaia; Johnson Gary R.; Chen Peijun; Hicks Paul B.; Davis Lori L.; Yoon Jean; Gleason Theresa C.; Vertrees Julia E.; Weingart Kimberly; Tal Ilanit; Scrymgeour Alexandra; Lawrence David D.; Planeta Beata; Thase Michael E.; Huang Grant D.; Zisook Sidney;
展开▼
作者单位

VA Connecticut Healthcare Syst Vet Affairs VA New England Mental Illness Res Edu 950 Campbell Ave;

VA Connecticut Healthcare Syst Cooperat Studies Program Coordinating Ctr 950 Campbell Ave;

Louis Stokes VA Med Ctr Cleveland OH USA;

Cent Texas Vet Healthcare Syst Temple TX USA;

Tuscaloosa VA Med Ctr Tuscaloosa AL USA;

VA Palo Alto Hlth Econ Resource Ctr Menlo Pk CA USA;

Off Res &

Dev Dept Vet Affairs Washington DC USA;

Clin Res Pharm Coordinating Ctr Cooperat Studies Program Albuquerque NM USA;

VA San Diego Healthcare Syst San Diego CA USA;

VA San Diego Healthcare Syst San Diego CA USA;

Clin Res Pharm Coordinating Ctr Cooperat Studies Program Albuquerque NM USA;

VA Connecticut Healthcare Syst Cooperat Studies Program Coordinating Ctr 950 Campbell Ave;

VA Connecticut Healthcare Syst Cooperat Studies Program Coordinating Ctr 950 Campbell Ave;

Philadelphia VA Med Ctr Philadelphia PA USA;

Off Res &

Dev Dept Vet Affairs Cooperat Studies Program Cent Off Washington DC USA;

VA San Diego Healthcare Syst San Diego CA USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医药、卫生;
关键词

相似文献

外文文献
中文文献
专利

1. Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment The VAST-D Randomized Clinical Trial [J] . Mohamed Somaia, Johnson Gary R., Chen Peijun, JAMA: the Journal of the American Medical Association . 2017,第2期

机译：抗抑郁切换对抗抑郁治疗患者抗抑郁治疗患者缓解抗抑郁治疗的影响
2. Dose Increase Versus Unchanged Continuation or Antidepressants After Initial Antidepressant Treatment Failure in Patients With Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized, Double-Blind Trials [J] . Rink Lena, Braun Cora, Bschor Tom, The journal of clinical psychiatry . 2018,第3期

机译：在重大抑郁症患者初始抗抑郁治疗失败后，剂量增加与未改变的延续或抗抑郁药患者：随机，双盲试验的系统审查和荟萃分析
3. Aripiprazole augmentation, antidepressant combination or switching therapy in patients with major depressive disorder who are partial- or non-responsive to current antidepressants: A multi-center, naturalistic study [J] . Changsu Han, Sheng-Min Wang, Ho-Jun Seo, Journal of psychiatric research . 2014,第Null期

机译：多发性，自然主义研究对患有部分抑郁症或对现有抗抑郁药无反应的重大抑郁症患者进行阿立哌唑增强，抗抑郁药联合治疗或转换治疗
4. Methylphenidate augmentation during antidepressant treatment for depression in HIV: a case report [C] . A Primatanti Annual Applied Science and Engineering Conference . 2019

机译：艾滋病毒抑郁症抗抑郁治疗期间的甲基酚酸酯增强：案例报告
5. Immunologic dimensions in major depressive disorder: An evaluation of clinical predictors and antidepressant immunomodulation in vivo and in vitro. [D] . Frank, Matthew G. 2001

机译：主要抑郁症的免疫学方面：体内和体外临床预测指标和抗抑郁药免疫调节的评估。
6. Double blinding requirement for validity claims in cognitive-behavioral therapy intervention trials for major depressive disorder. Analysis of Hollon S et al. Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder: a randomized clinical trial [O] . Douglas Berger, Arif Khan, Rebecca Graham -1

机译：对重度抑郁症的认知行为疗法干预试验中有效性要求的双盲要求。分析Hollon S等抗抑郁药与单纯抗抑郁药的认知疗法对重度抑郁症康复率的影响：一项随机临床试验
7. A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial [O] . Changsu Han, Sheng-Min Wang, Won-Myong Bahk, 2018

机译：针对主要抑郁症患者的药物基因组抗抑郁药治疗：8周，随机单盲临床试验的结果

Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment The VAST-D Randomized Clinical Trial

摘要

著录项

相似文献

相关主题

期刊订阅